Comparative Pharmacology
Head-to-head clinical analysis: DALIRESP versus ROFLUMILAST.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DALIRESP versus ROFLUMILAST.
DALIRESP vs ROFLUMILAST
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Selective phosphodiesterase 4 (PDE4) inhibitor that reduces inflammation by increasing intracellular cAMP levels, thereby inhibiting inflammatory cell activity.
Selective phosphodiesterase 4 (PDE4) inhibitor; increases intracellular cyclic AMP levels, reducing inflammation and relaxing smooth muscle in the airways.
500 mg orally once daily
500 mcg orally once daily.
None Documented
None Documented
The terminal elimination half-life is approximately 17-21 hours, supporting once-daily dosing.
Terminal elimination half-life approximately 29-30 hours in COPD patients, allowing once-daily dosing. Steady-state reached in 4-5 days.
Clinical Note
moderateRoflumilast + Budesonide
"Roflumilast may increase the immunosuppressive activities of Budesonide."
Clinical Note
moderateRoflumilast + Prednisolone
"Roflumilast may increase the immunosuppressive activities of Prednisolone."
Clinical Note
moderateRoflumilast + Deflazacort
"Roflumilast may increase the immunosuppressive activities of Deflazacort."
Clinical Note
moderateRoflumilast + Cortisone acetate
Approximately 70% of the dose is excreted via the feces (primarily as unchanged drug and glucuronide conjugates) and 20% via the urine (mostly as metabolites).
Primarily hepatic metabolism via CYP3A4 and CYP1A2, with metabolites excreted in urine (40-50% as metabolites) and feces (40-50% as metabolites). Less than 1% excreted unchanged.
Category C
Category C
Phosphodiesterase-4 Inhibitor
Phosphodiesterase-4 Inhibitor
"Roflumilast may increase the immunosuppressive activities of Cortisone acetate."